EF Hutton analyst Tony Butler initiated coverage of Adaptimmune with a Buy rating and $10 price target. Adaptimmune is a cell therapy company whose pipeline is centered on its comprehensive T-cell therapeutic platform, Butler tells investors in a research note. The analyst sees a high probability of the approval of the Biologics License Application for afami-cel to treat synovial sarcoma.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ADAP: